Analyst Ratings for [CERT] Certara Inc

9/29/25	Initiated	Buy	X
CERT Certara Craig Hallum
$16
7/3/25	Resumed	Equal-Weight	X
CERT Certara Morgan Stanley
$16
5/8/25	Upgrades	Eq Weight Overweight	X
CERT Certara Barclays
$14
2/27/25	Initiated	Buy	X
CERT Certara TD Cowen
$16
9/27/24	Upgrades	Neutral Buy	X
CERT Certara UBS
$16
4/10/24	Upgrades	Sec Weight Overweight	X
CERT Certara KeyBanc Capital Markets
$23
4/4/24	Initiated	Mkt Perform	X
CERT Certara JMP Securities
2/26/24	Initiated	Market Perform	X
CERT Certara Leerink Partners
$19
12/7/23	Initiated	Neutral	X
CERT Certara UBS
$17
12/5/23	Initiated	Sector Weight	X
CERT Certara KeyBanc Capital Markets
8/22/23	Downgrades	Buy Hold	X
CERT Certara Jefferies
$24.50 $17
8/10/23	Downgrades	Outperform Mkt Perform	X
CERT Certara William Blair
4/12/23	Initiated	Overweight	X
CERT Certara Stephens
$28
4/3/23	Downgrades	Overweight Eq Weight	X
CERT Certara Barclays
$25
12/14/22	Downgrades	Outperform Neutral	X
CERT Certara Robert W. Baird
$17 $19
9/8/22	Initiated	Buy	X
CERT Certara Berenberg
$23
8/25/22	Initiated	Outperform	X
CERT Certara Credit Suisse
$22
7/1/22	Initiated	Overweight	X
CERT Certara Piper Sandler
$28
1/11/22	Upgrades	Hold Buy	X
CERT Certara Jefferies
$31
7/23/21	Initiated	Outperform	X
CERT Certara Robert W. Baird
$30
3/3/21	Initiated	Overweight	X
CERT Certara Barclays
$40
1/6/21	Initiated	Equal-Weight	X
CERT Certara Morgan Stanley
$35
1/5/21	Initiated	Buy	X
CERT Certara BofA Securities
$41
1/5/21	Initiated	Neutral	X
CERT Certara Credit Suisse
$35
1/5/21	Initiated	Hold	X
CERT Certara Jefferies
$33
1/5/21	Initiated	Outperform	X
CERT Certara William Blair

CERT Certara Inc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies and academic institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.